{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,11]],"date-time":"2024-08-11T15:11:11Z","timestamp":1723389071196},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,9,2]],"date-time":"2014-09-02T00:00:00Z","timestamp":1409616000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/s13023-014-0134-4","type":"journal-article","created":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T14:45:46Z","timestamp":1409582746000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The European Gaucher Alliance: a survey of member patient organisations\u2019 activities, healthcare environments and concerns"],"prefix":"10.1186","volume":"9","author":[{"given":"Irena","family":"\u017dnidar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanya","family":"Collin-Histed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Niemeyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Parkkinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Grethe","family":"Lauridsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Zari\u0146a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yossi","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy","family":"Manuel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,9,2]]},"reference":[{"key":"134_CR1","first-page":"299","volume":"6","author":"TM Cox","year":"2010","unstructured":"Cox TM: Gaucher disease: clinical profile and therapeutic developments. Biologics. 2010, 6: 299-313.","journal-title":"Biologics"},{"key":"134_CR2","doi-asserted-by":"publisher","first-page":"E26","DOI":"10.1002\/clc.20348","volume":"33","author":"N Cindik","year":"2010","unstructured":"Cindik N, Ozcay F, S\u00fcren D, Akkoyun I, G\u00f6kdemir M, Varan B, Alehan F, Ozbek N, Tokel K: Gaucher disease with communicating hydrocephalus and cardiac involvement. Clin Cardiol. 2010, 33: E26-E30. 10.1002\/clc.20348.","journal-title":"Clin Cardiol"},{"key":"134_CR3","doi-asserted-by":"publisher","first-page":"2835","DOI":"10.1001\/archinte.160.18.2835","volume":"160","author":"J Charrow","year":"2000","unstructured":"Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G, Rosenbloom BE, Scott CR, Wappner RS, Weinreb NJ, Zimran A: The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med. 2000, 160: 2835-2843. 10.1001\/archinte.160.18.2835.","journal-title":"Arch Intern Med"},{"key":"134_CR4","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1182\/blood.V84.7.2374.2374","volume":"84","author":"A Zimran","year":"1994","unstructured":"Zimran A, Elstein D, Abrahamov A, Dale GL, Aker M, Matzner Y: Significance of abnormal neutrophil chemotaxis in Gaucher\u2019s disease. Blood. 1994, 84: 2374-2375.","journal-title":"Blood"},{"key":"134_CR5","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1001\/archpedi.160.6.603","volume":"160","author":"P Kaplan","year":"2006","unstructured":"Kaplan P, Andersson HC, Kacena KA, Yee JD: The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis. Arch Pediatr Adolesc Med. 2006, 160: 603-608. 10.1001\/archpedi.160.6.603.","journal-title":"Arch Pediatr Adolesc Med"},{"key":"134_CR6","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.bcmd.2009.04.003","volume":"43","author":"A Zimran","year":"2009","unstructured":"Zimran A, Morris E, Mengel E, Kaplan P, Belmatoug N, Hughes DA, Malinova V, Heitner R, Sobreira E, Mrsi\u0107 M, Granovsky-Grisaru S, Amato D, vom Dahl S: The female Gaucher patient: the impact of enzyme replacement therapy around key reproductive events (menstruation, pregnancy and menopause). Blood Cells Mol Dis. 2009, 43: 264-288. 10.1016\/j.bcmd.2009.04.003.","journal-title":"Blood Cells Mol Dis"},{"key":"134_CR7","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s10545-008-0779-z","volume":"31","author":"TM Cox","year":"2008","unstructured":"Cox TM, Aerts JM, Belmatoug N, Cappellini MD, vom Dahl S, Goldblatt J, Grabowski GA, Hollak CE, Hwu P, Maas M, Martins AM, Mistry PK, Pastores GM, Tylki-Szymanska A, Yee J, Weinreb N: Management of non-neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring. J Inherit Metab Dis. 2008, 31: 319-336. 10.1007\/s10545-008-0779-z.","journal-title":"J Inherit Metab Dis"},{"key":"134_CR8","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1093\/brain\/awq198","volume":"133","author":"M Biegstraaten","year":"2010","unstructured":"Biegstraaten M, Mengel E, Mar\u00f3di L, Petakov M, Niederau C, Giraldo P, Hughes D, Mrsic M, Mehta A, Hollak CE, van Schaik IN: Peripheral neuropathy in adult type 1 Gaucher disease: a 2-year prospective observational study. Brain. 2010, 133: 2909-2919. 10.1093\/brain\/awq198.","journal-title":"Brain"},{"key":"134_CR9","doi-asserted-by":"publisher","first-page":"4569","DOI":"10.1182\/blood-2004-12-4672","volume":"105","author":"BE Rosenbloom","year":"2005","unstructured":"Rosenbloom BE, Weinreb NJ, Zimran A, Kacena KA, Charrow J, Ward E: Gaucher disease and cancer incidence: a study from the Gaucher Registry. Blood. 2005, 105: 4569-4572. 10.1182\/blood-2004-12-4672.","journal-title":"Blood"},{"key":"134_CR10","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.bcmd.2010.10.006","volume":"46","author":"B Rosenbloom","year":"2011","unstructured":"Rosenbloom B, Balwani M, Bronstein JM, Kolodny E, Sathe S, Gwosdow AR, Taylor JS, Cole JA, Zimran A, Weinreb NJ: The incidence of Parkinsonism in patients with type 1 Gaucher disease: data from the ICGG Gaucher Registry. Blood Cells Mol Dis. 2011, 46: 95-102. 10.1016\/j.bcmd.2010.10.006.","journal-title":"Blood Cells Mol Dis"},{"key":"134_CR11","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s10545-009-9009-6","volume":"33","author":"A Tylki-Szyma\u0144ska","year":"2010","unstructured":"Tylki-Szyma\u0144ska A, Vellodi A, El-Beshlawy A, Cole JA, Kolodny E: Neuronopathic Gaucher disease: demographic and clinical features of 131 patients enrolled in the international collaborative Gaucher group neurological outcomes subregistry. J Inherit Metab Dis. 2010, 33: 339-346. 10.1007\/s10545-009-9009-6.","journal-title":"J Inherit Metab Dis"},{"key":"134_CR12","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1023\/A:1025902113005","volume":"26","author":"TM Cox","year":"2003","unstructured":"Cox TM, Aerts JM, Andria G, Beck M, Belmatoug N, Bembi B, Chertkoff R, Vom Dahl S, Elstein D, Erikson A, Giralt M, Heitner R, Hollak C, Hrebicek M, Lewis S, Mehta A, Pastores GM, Rolfs A, Miranda MC, Zimran A: The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement. J Inherit Metab Dis. 2003, 26: 513-526. 10.1023\/A:1025902113005.","journal-title":"J Inherit Metab Dis"},{"key":"134_CR13","doi-asserted-by":"publisher","first-page":"4095","DOI":"10.1182\/blood-2010-06-293902","volume":"116","author":"E Lukina","year":"2010","unstructured":"Lukina E, Watman N, Arreguin EA, Dragosky M, Iastrebner M, Rosenbaum H, Phillips M, Pastores GM, Kamath RS, Rosenthal DI, Kaper M, Singh T, Puga AC, Peterschmitt MJ: Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study. Blood. 2010, 116: 4095-4098. 10.1182\/blood-2010-06-293902.","journal-title":"Blood"},{"key":"134_CR14","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s10545-012-9528-4","volume":"36","author":"NJ Weinreb","year":"2013","unstructured":"Weinreb NJ, Goldblatt J, Villalobos J, Charrow J, Cole JA, Kerstenetzky M, vom Dahl S, Hollak C: Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment. J Inherit Metab Dis. 2013, 36: 543-553. 10.1007\/s10545-012-9528-4.","journal-title":"J Inherit Metab Dis"},{"key":"134_CR15","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.bcmd.2012.11.001","volume":"50","author":"L van Dussen","year":"2013","unstructured":"van Dussen L, Zimran A, Akkerman EM, Aerts JM, Petakov M, Elstein D, Rosenbaum H, Aviezer D, Brill-Almon E, Chertkoff R, Maas M, Hollak CE: Taliglucerase alfa leads to favorable bone marrow responses in patients with type I Gaucher disease. Blood Cells Mol Dis. 2013, 50: 206-211. 10.1016\/j.bcmd.2012.11.001.","journal-title":"Blood Cells Mol Dis"},{"key":"134_CR16","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/ajh.23381","volume":"88","author":"DE Gonzalez","year":"2013","unstructured":"Gonzalez DE, Turkia HB, Lukina EA, Kisinovsky I, Dridi MF, Elstein D, Zahrieh D, Crombez E, Bhirangi K, Barton NW, Zimran A: Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: results from a randomized, double-blind, multinational, phase 3 study. Am J Hematol. 2013, 88: 166-171. 10.1002\/ajh.23381.","journal-title":"Am J Hematol"},{"key":"134_CR17","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.bcmd.2013.04.005","volume":"51","author":"DJ Kuter","year":"2013","unstructured":"Kuter DJ, Mehta A, Hollak CE, Giraldo P, Hughes D, Belmatoug N, Brand M, Muller A, Schaaf B, Giorgino R, Zimran A: Miglustat therapy in type 1 Gaucher disease: clinical and safety outcomes in a multicenter retrospective cohort study. Blood Cells Mol Dis. 2013, 51: 116-124. 10.1016\/j.bcmd.2013.04.005.","journal-title":"Blood Cells Mol Dis"},{"key":"134_CR18","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1097\/00125817-200211000-00005","volume":"4","author":"KA Grinzaid","year":"2002","unstructured":"Grinzaid KA, Geller E, Hanna SL, Elsas LJ: Cessation of enzyme replacement therapy in Gaucher disease. Genet Med. 2002, 4: 427-433. 10.1097\/00125817-200211000-00005.","journal-title":"Genet Med"},{"key":"134_CR19","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.jpeds.2007.02.057","volume":"151","author":"G Drelichman","year":"2007","unstructured":"Drelichman G, Ponce E, Basack N, Freigeiro D, Aversa L, Graciela E, Kohan R: Clinical consequences of interrupting enzyme replacement therapy in children with type 1 Gaucher disease. J Pediatr. 2007, 151: 197-201. 10.1016\/j.jpeds.2007.02.057.","journal-title":"J Pediatr"},{"key":"134_CR20","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.ymgme.2011.08.004","volume":"104","author":"O Goker-Alpan","year":"2011","unstructured":"Goker-Alpan O: Therapeutic approaches to bone pathology in Gaucher disease: past, present and future. Mol Genet Metab. 2011, 104: 438-447. 10.1016\/j.ymgme.2011.08.004.","journal-title":"Mol Genet Metab"},{"key":"134_CR21","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1615\/CritRevOncog.2013006145","volume":"18","author":"PK Mistry","year":"2013","unstructured":"Mistry PK, Taddei T, vom Dahl S, Rosenbloom BE: Gaucher disease and malignancy: a model for cancer pathogenesis in an inborn error of metabolism. Crit Rev Oncog. 2013, 18: 235-246. 10.1615\/CritRevOncog.2013006145.","journal-title":"Crit Rev Oncog"},{"key":"134_CR22","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1002\/ajh.20908","volume":"82","author":"PK Mistry","year":"2007","unstructured":"Mistry PK, Sadan S, Yang R, Yee J, Yang M: Consequences of diagnostic delays in type 1 Gaucher disease: the need for greater awareness among hematologists-oncologists and an opportunity for early diagnosis and intervention. Am J Hematol. 2007, 82: 697-701. 10.1002\/ajh.20908.","journal-title":"Am J Hematol"},{"key":"134_CR23","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.bcmd.2012.11.004","volume":"50","author":"AS Thomas","year":"2013","unstructured":"Thomas AS, Mehta AB, Hughes DA: Diagnosing Gaucher disease: an on-going need for increased awareness amongst haematologists. Blood Cells Mol Dis. 2013, 50: 212-217. 10.1016\/j.bcmd.2012.11.004.","journal-title":"Blood Cells Mol Dis"},{"key":"134_CR24","unstructured":"Limb L, Nutt S, Sen A: Rare Disease UK: Experiences of Rare Diseases; An Insight from Patients and Families. December 2010. ., [http:\/\/www.raredisease.org.uk\/documents\/RDUK-Family-Report.pdf]"},{"key":"134_CR25","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1159\/000342758","volume":"3","author":"M Mavris","year":"2012","unstructured":"Mavris M, Le Cam Y: Involvement of patient organisations in research and development of orphan drugs for rare diseases in Europe. Mol Syndromol. 2012, 3: 237-243.","journal-title":"Mol Syndromol"},{"key":"134_CR26","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.bcmd.2006.05.002","volume":"37","author":"I Kesselman","year":"2006","unstructured":"Kesselman I, Elstein D, Israeli A, Chertkoff R, Zimran A: National health budgets for expensive orphan drugs: Gaucher disease in Israel as a model. Blood Cells Mol Dis. 2006, 37: 46-49. 10.1016\/j.bcmd.2006.05.002.","journal-title":"Blood Cells Mol Dis"},{"key":"134_CR27","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1007\/s10545-008-0868-z","volume":"31","author":"C Fairley","year":"2008","unstructured":"Fairley C, Zimran A, Phillips M, Cizmarik M, Yee J, Weinreb N, Packman S: Phenotypic heterogeneity of N370S homozygotes with type I Gaucher disease: an analysis of 798 patients from the ICGG Gaucher registry. J Inherit Metab Dis. 2008, 31: 738-744. 10.1007\/s10545-008-0868-z.","journal-title":"J Inherit Metab Dis"},{"key":"134_CR28","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1007\/s00415-013-6980-5","volume":"260","author":"T Hundsberger","year":"2013","unstructured":"Hundsberger T, Rohrbach M, Kern L, R\u00f6sler KM: Swiss national guideline for reimbursement of enzyme replacement therapy in late-onset Pompe disease. J Neurol. 2013, 260: 2279-2285. 10.1007\/s00415-013-6980-5.","journal-title":"J Neurol"},{"key":"134_CR29","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1750-1172-8-135","volume":"8","author":"H Hyry","year":"2013","unstructured":"Hyry H, Roos JCP, Manuel J, Cox TM: The legal imperative for treating rare disorders. Orphanet J of Rare Dis. 2013, 8: 135-10.1186\/1750-1172-8-135. [http:\/\/ojrd.com\/content\/8\/1\/135]","journal-title":"Orphanet J of Rare Dis"},{"key":"134_CR30","doi-asserted-by":"publisher","first-page":"e5727","DOI":"10.1136\/bmj.e5727","volume":"345","author":"CJ Hendriksz","year":"2012","unstructured":"Hendriksz CJ, Mehta AB, Wraith JE, Jones SE, Ramaswami U, Deegan P, Lachmann R, Murphy E, Hiwot T, Vijay SV, Stewart F, Cleary M: Transfer of high cost drugs to NICE risks fragmentation of care of rare diseases. BMJ. 2012, 345: e5727-10.1136\/bmj.e5727.","journal-title":"BMJ"},{"key":"134_CR31","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.bcmd.2009.09.006","volume":"44","author":"CE Hollak","year":"2010","unstructured":"Hollak CE, vom Dahl S, Aerts JM, Belmatoug N, Bembi B, Cohen Y, Collin-Histed T, Deegan P, van Dussen L, Giraldo P, Mengel E, Michelakakis H, Manuel J, Hrebicek M, Parini R, Reinke J, di Rocco M, Pocovi M, Sa Miranda MC, Tylki-Szymanska A, Zimran A, Cox TM: Force majeure: therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease. Blood Cells Mol Dis. 2010, 44: 41-47. 10.1016\/j.bcmd.2009.09.006.","journal-title":"Blood Cells Mol Dis"},{"key":"134_CR32","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1182\/blood-2011-04-308890","volume":"118","author":"A Zimran","year":"2011","unstructured":"Zimran A: How I treat Gaucher disease. Blood. 2011, 118: 1463-1471. 10.1182\/blood-2011-04-308890.","journal-title":"Blood"},{"key":"134_CR33","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1517\/14656560903270520","volume":"10","author":"CE Hollak","year":"2009","unstructured":"Hollak CE, de Fost M, van Dussen L, Vom Dahl S, Aerts JM: Enzyme therapy for the treatment of type 1 Gaucher disease: clinical outcomes and dose - response relationships. Expert Opin Pharmacother. 2009, 10: 2641-2652. 10.1517\/14656560903270520.","journal-title":"Expert Opin Pharmacother"},{"key":"134_CR34","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1097\/GIM.0b013e31818e2c19","volume":"11","author":"GA Grabowski","year":"2009","unstructured":"Grabowski GA, Kacena K, Cole JA, Hollak CE, Zhang L, Yee J, Mistry PK, Zimran A, Charrow J, vom Dahl S: Dose-response relationships for enzyme replacement therapy with imiglucerase\/alglucerase in patients with Gaucher disease type 1. Genet Med. 2009, 11: 92-100. 10.1097\/GIM.0b013e31818e2c19.","journal-title":"Genet Med"},{"key":"134_CR35","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1097\/01.GIM.0000153660.88672.3C","volume":"7","author":"HC Andersson","year":"2005","unstructured":"Andersson HC, Charrow J, Kaplan P, Mistry P, Pastores GM, Prakash-Cheng A, Rosenbloom BE, Scott CR, Wappner RS, Weinreb NJ: Individualization of long-term enzyme replacement therapy for Gaucher disease. Genet Med. 2005, 7: 105-110. 10.1097\/01.GIM.0000153660.88672.3C.","journal-title":"Genet Med"},{"key":"134_CR36","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/8904_2012_158","volume":"7","author":"L Deroma","year":"2013","unstructured":"Deroma L, Sechi A, Dardis A, Macor D, Liva G, Ciana G, Bembi B: Did the temporary shortage in supply of imiglucerase have clinical consequences? Retrospective observational study on 34 italian Gaucher type I patients. JIMD Rep. 2013, 7: 117-122. 10.1007\/8904_2012_158.","journal-title":"JIMD Rep"},{"key":"134_CR37","unstructured":"European Commission: Centres of Reference for rare diseases in Europe: State-of-the-art in 2006 and Recommendations of the Rare Diseases Task Force.., [http:\/\/ec.europa.eu\/health\/archive\/ph_threats\/non_com\/docs\/contribution_policy.pdf]"},{"key":"134_CR38","unstructured":"European Commission: EUCERD Recommendations on Quality Criteria for Centres of Expertise for Rare Diseases in Member States. 24 October 2011. ., [http:\/\/www.EUCERD.eu\/upload\/file\/EUCERDRecommendationCE.pdf]"},{"key":"134_CR39","unstructured":"Aym\u00e9 S, Rodwell C: 2013 Report on the State of the Art of Rare Disease Activities in Europe. July 2013. ., [http:\/\/www.eucerd.eu\/upload\/file\/Reports\/2013ReportStateofArtRDActivities.pdf]"},{"key":"134_CR40","unstructured":"European Commission: The Council Recommendation on an action in the field of rare diseases (8 June 2009) recommends that MS elaborate and adopt, by 2013, a national plan or strategy for rare diseases.., [http:\/\/ec.europa.eu\/health\/rare_diseases\/national_plans\/detailed\/index_en.htm]"},{"key":"134_CR41","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s10897-013-9579-1","volume":"22","author":"R Freedman","year":"2013","unstructured":"Freedman R, Sahhar M, Curnow L, Lee J, Peters H: Receiving enzyme replacement therapy for a lysosomal storage disorder: a preliminary exploration of the experiences of young patients and their families. J Genet Couns. 2013, 22: 517-532. 10.1007\/s10897-013-9579-1.","journal-title":"J Genet Couns"},{"key":"134_CR42","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1002\/ajmg.a.33527","volume":"152A","author":"W Packman","year":"2010","unstructured":"Packman W, Crosbie TW, Behnken M, Eudy K, Packman S: Living with Gaucher disease: emotional health, psychosocial needs and concerns of individuals with Gaucher disease. Am J Med Genet A. 2010, 152A: 2002-2010. 10.1002\/ajmg.a.33527.","journal-title":"Am J Med Genet A"},{"issue":"2","key":"134_CR43","first-page":"doi:10.4088\/PCC","volume":"15","author":"B Voinov","year":"2013","unstructured":"Voinov B, Richie WD, Bailey RK: Depression and chronic diseases: it is time for a synergistic mental health and primary care approach. Prim Care Companion CNS Disord. 2013, 15 (2): doi:10.4088\/PCC.12r01468-","journal-title":"Prim Care Companion CNS Disord"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-014-0134-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-014-0134-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-014-0134-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-014-0134-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,16]],"date-time":"2023-07-16T09:52:35Z","timestamp":1689501155000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-014-0134-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,2]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["134"],"URL":"https:\/\/doi.org\/10.1186\/s13023-014-0134-4","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,2]]},"assertion":[{"value":"16 April 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"134"}}